AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 22-E-05-014.01
CMS should encourage Part D plans to increase access to and use of biosimilars.
The recommendation, in the publisher's words
CMS should encourage Part D plans to increase access to and use of biosimilars.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- March 29, 2022
- Report
- Medicare Part D and Beneficiaries Could Realize Significant Spending Reductions With Increased Biosimilar Use (OEI-05-20-00480) · find it at HHS OIG
- Kind of report
- Evaluation
- Agency response
- Concur (as recorded by the publisher)
- Closed
- October 20, 2025 (publisher's date)
- Publisher topics
- Financial Stewardship, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- Closed, with status “Closed Implemented”. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
1 more, of which 0 are open in the publisher's file.
- CMS should Monitor Part D plans� submitted formularies to determine whether they discourage beneficiaries from using biosimilars.HHS OIG 22-E-05-014.02 · issued Mar 29, 2022 · closed Mar 14, 2024Closed Implemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.